Drinabant
Cat. No.：YN322488
| 产品名称: | Drinabant |
| CAS No.: | 358970-97-5 |
| Chemical Name: | N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)-methanesulfonamide |
| Synonyms: | AVE1625 |
| 分子量: | 497.4 |
| 分子式: | C23H20Cl2F2N2O2S |
| SMILES: | Clc1ccc(cc1)C(c1ccc(Cl)cc1)N1CC(C1)N(c1cc(F)cc(F)c1)S(=O)(=O)C |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Drinabant (AVE1625) 是具有口服活性的CB1受体的拮抗剂。Drinabant (AVE1625) 抑制hCB1-R 和 rCB1-R 激动剂刺激的钙信号的IC50值分别为 25 nM 和 10 nM。对 hCB2-R 无活性。 |
| IC50和靶点: | [{name:"hCB1-R:25 nM (IC50)"},{name: "rCB1-R:10 nM (IC50)"},{name: "CB2:10000 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Howlett, A.C., Song, C., Berglund, B.A., et al.Characterization of CB1 cannabinoid receptors using receptor peptide fragments and site-directed antibodiesMol. Pharmacol.53(3),504-510(1998)
Gómez, R., Navarro, M., Ferrer, B., et al.A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feedingJ. Neurosci.22(21),9612-9617(2002)
Mackie, K.Cannabinoid receptors as therapeutic targetsAnnu. Rev. Pharmacol. Toxicol.46,101-122(2006)
Borowsky, B., Stevens, R., Mark, B., et al.AVE1625, a cannabinoid CB1 antagonist, as a co-treatment for Schizophrenia: Improvement in cognitive function and reduction of antipsychotic-side effects in animal modelsNeuropsychopharmacology30,S116-S117(2005)
Herling, A.W., Gossel, M., Haschke, G., et al.The CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in wistar ratsAm. J. Physiol. Endocrinol. Metab.293(3),E826-E832(2007)
